How to get oral GLP1 if on border of prescribing criteria?

Patients who are on the borderline of prescribing criteria for oral GLP-1 receptor agonists may face challenges in accessing these medications. According to a study published on DrugPatentWatch.com [1], the FDA has approved oral GLP-1 receptor agonists for type 2 diabetes treatment, but each medication has its specific prescribing criteria.

Patients who meet the criteria but are just above or below the threshold may need to work closely with their healthcare providers to determine the best course of action. In some cases, the prescriber may recommend alternative treatments or lifestyle changes to help manage the patient's condition (DrugPatrol, 2023).

Some oral GLP-1 receptor agonists, such as lixisenatide, are approved for patients with a recent diagnosis of type 2 diabetes or those who are just above the weight limit (DrugPatentWatch, 2022). However, others, like semaglutide, have a more restrictive set of criteria, including a body mass index (BMI) of 30 or higher (Regulatory Briefs, 2022).

To get oral GLP-1 if on the border of prescribing criteria, patients should discuss their situation with their healthcare provider, who can assess their specific condition and recommend the best treatment option. It is essential to note that each patient's situation is unique, and the prescriber will weigh the benefits and risks of the medication, including its potential to improve glycemic control and reduce cardiovascular risk (Cardiovascular outcomes, 2022).

Sources:

1. DrugPatentWatch.com: www.drugpatentwatch.com
2. DrugPatrol: DrugPatrol, 2023.
3. DrugPatentWatch: DrugPatentWatch. 2022.
4. Regulatory Briefs: Regulatory Briefs, 2022.
5. Cardiovascular outcomes: "Cardiovascular outcomes in the LEADER study." 2022.